The CEO of Life Clips is also a director of this company.
Kalytera is developing a clinical-stage cannabidiol (“CBD”) medicine to prevent and treat Graft versus Host Disease (“GvHD”). GvHD is a multisystem disorder that is a common, life-threatening complication of hematopoietic stem cell transplant (“HCT”) procedures. GvHD occurs when the transplanted donor cells attack the patient’s organs, including the skin, gastrointestinal tract, liver, lungs, and eyes. GvHD is associated with acute and chronic illness, infections, disability, reduced quality of life, and death. Learn more >>